170 related articles for article (PubMed ID: 30684598)
1. In vitro dissolution testing of respirable size anti-tubercular drug particles using a small volume dissolution apparatus.
Eedara BB; Tucker IG; Das SC
Int J Pharm; 2019 Mar; 559():235-244. PubMed ID: 30684598
[TBL] [Abstract][Full Text] [Related]
2. Crystalline adduct of moxifloxacin with trans-cinnamic acid to reduce the aqueous solubility and dissolution rate for improved residence time in the lungs.
Eedara BB; Tucker IG; Zujovic ZD; Rades T; Price JR; Das SC
Eur J Pharm Sci; 2019 Aug; 136():104961. PubMed ID: 31220546
[TBL] [Abstract][Full Text] [Related]
3. Carrier-free combination dry powder inhaler formulation of ethionamide and moxifloxacin for treating drug-resistant tuberculosis.
Momin MAM; Sinha S; Tucker IG; Das SC
Drug Dev Ind Pharm; 2019 Aug; 45(8):1321-1331. PubMed ID: 31014129
[TBL] [Abstract][Full Text] [Related]
4. A STELLA simulation model for in vitro dissolution testing of respirable size particles.
Eedara BB; Tucker IG; Das SC
Sci Rep; 2019 Dec; 9(1):18522. PubMed ID: 31811249
[TBL] [Abstract][Full Text] [Related]
5. Dry powder inhalers: An overview of the in vitro dissolution methodologies and their correlation with the biopharmaceutical aspects of the drug products.
Velaga SP; Djuris J; Cvijic S; Rozou S; Russo P; Colombo G; Rossi A
Eur J Pharm Sci; 2018 Feb; 113():18-28. PubMed ID: 28887232
[TBL] [Abstract][Full Text] [Related]
6. Bedaquiline containing triple combination powder for inhalation to treat drug-resistant tuberculosis.
Rangnekar B; Momin MAM; Eedara BB; Sinha S; Das SC
Int J Pharm; 2019 Oct; 570():118689. PubMed ID: 31513868
[TBL] [Abstract][Full Text] [Related]
7. DissolvIt: An In Vitro Method for Simulating the Dissolution and Absorption of Inhaled Dry Powder Drugs in the Lungs.
Gerde P; Malmlöf M; Havsborn L; Sjöberg CO; Ewing P; Eirefelt S; Ekelund K
Assay Drug Dev Technol; 2017; 15(2):77-88. PubMed ID: 28322599
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of Ethionamide Delivered in Spray-Dried Microparticles to the Lungs of Guinea Pigs.
Garcia-Contreras L; Padilla-Carlin DJ; Sung J; VerBerkmoes J; Muttil P; Elbert K; Peloquin C; Edwards D; Hickey A
J Pharm Sci; 2017 Jan; 106(1):331-337. PubMed ID: 27842973
[TBL] [Abstract][Full Text] [Related]
9. Aerosolization, Drug Permeation and Cellular Interaction of Dry Powder Pulmonary Formulations of Corticosteroids with Hydroxypropyl-β-Cyclodextrin as a Solubilizer.
Vartiainen V; Bimbo LM; Hirvonen J; Kauppinen EI; Raula J
Pharm Res; 2017 Jan; 34(1):25-35. PubMed ID: 27604893
[TBL] [Abstract][Full Text] [Related]
10. In-Vitro In-Vivo Correlation (IVIVC) of Inhaled Products Using Twin Stage Impinger.
Al Ayoub Y; Buzgeia A; Almousawi G; Mazhar HRA; Alzouebi B; Gopalan RC; Assi KH
J Pharm Sci; 2022 Feb; 111(2):395-402. PubMed ID: 34599997
[TBL] [Abstract][Full Text] [Related]
11. Effect of particle deposition density of dry powders on the results produced by an in vitro test system simulating dissolution- and absorption rates in the lungs.
Malmlöf M; Nowenwik M; Meelich K; Rådberg I; Selg E; Burns J; Mascher H; Gerde P
Eur J Pharm Biopharm; 2019 Jun; 139():213-223. PubMed ID: 30862480
[TBL] [Abstract][Full Text] [Related]
12. Preparation and optimization of a dry powder for inhalation of second-line anti-tuberculosis drugs.
Ranjan R; Srivastava A; Bharti R; Ray L; Singh J; Misra A
Int J Pharm; 2018 Aug; 547(1-2):150-157. PubMed ID: 29852204
[TBL] [Abstract][Full Text] [Related]
13. Phospholipid-based pyrazinamide spray-dried inhalable powders for treating tuberculosis.
Eedara BB; Tucker IG; Das SC
Int J Pharm; 2016 Jun; 506(1-2):174-83. PubMed ID: 27091294
[TBL] [Abstract][Full Text] [Related]
14. Development and Evaluation of Chitosan Microparticles Based Dry Powder Inhalation Formulations of Rifampicin and Rifabutin.
Pai RV; Jain RR; Bannalikar AS; Menon MD
J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):179-95. PubMed ID: 26406162
[TBL] [Abstract][Full Text] [Related]
15. Dissolution testing of powders for inhalation: influence of particle deposition and modeling of dissolution profiles.
May S; Jensen B; Weiler C; Wolkenhauer M; Schneider M; Lehr CM
Pharm Res; 2014 Nov; 31(11):3211-24. PubMed ID: 24852894
[TBL] [Abstract][Full Text] [Related]
16. Solid dispersions of itraconazole for inhalation with enhanced dissolution, solubility and dispersion properties.
Duret C; Wauthoz N; Sebti T; Vanderbist F; Amighi K
Int J Pharm; 2012 May; 428(1-2):103-13. PubMed ID: 22414388
[TBL] [Abstract][Full Text] [Related]
17. Spray-Dried PulmoSphere™ Formulations for Inhalation Comprising Crystalline Drug Particles.
Weers JG; Miller DP; Tarara TE
AAPS PharmSciTech; 2019 Feb; 20(3):103. PubMed ID: 30734187
[TBL] [Abstract][Full Text] [Related]
18. Ranking in Vitro Dissolution of Inhaled Micronized Drug Powders including a Candidate Drug with Two Different Particle Sizes.
Franek F; Fransson R; Thörn H; Bäckman P; Andersson PU; Tehler U
Mol Pharm; 2018 Nov; 15(11):5319-5326. PubMed ID: 30299965
[TBL] [Abstract][Full Text] [Related]
19. Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations.
Le VN; Robins E; Flament MP
Eur J Pharm Biopharm; 2012 Apr; 80(3):596-603. PubMed ID: 22198291
[TBL] [Abstract][Full Text] [Related]
20. Pulmonary Dissolution of Poorly Soluble Compounds Studied in an ex Vivo Rat Lung Model.
Eriksson J; Thörn H; Sjögren E; Holmstén L; Rubin K; Lennernäs H
Mol Pharm; 2019 Jul; 16(7):3053-3064. PubMed ID: 31136181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
